"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

"The brain changes all the time when kids are growing up," she said. It could be one of the reasons why immunotherapy, which ...

Early results from a trial of the company’s Lunit SCOPE system found patients examined with the device saw a 35% lower risk ...

Based on the latest recommendation, the company anticipates receiving marketing authorisation for the system in the first ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...

Mesothelioma is connected to asbestos exposure, and its symptoms typically don’t appear until decades after exposure.

A genetically engineered virus that is linked to the common cold has shown promise as a treatment for aggressive brain ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

US FDA clears SystImmune’s IND application for BL-M17D1 in advanced solid tumours: Redmond, Washington Monday, November 11, 2024, 14:00 Hrs [IST] SystImmune, Inc (SystImmune), a ...

A twenty-year study of breast cancer risks could allow doctors to anticipate and prevent tumours before they even have the ...

A research team at Lund University in Sweden has discovered a certain type of cells – foam cells – in patients with the aggressive brain tumour glioblastoma. It has been shown how these cells ...